Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyadic International (NQ: DYAI )

1.620 +0.230 (+16.55%)
Streaming Delayed Price Updated: 10:16 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dyadic International

< Previous 1 2 3 Next >
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at World Vaccine Congress Washington 2023
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Participate in Two Upcoming Investor Conferences
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Announces Sale of Equity Interest in Alphazyme
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA... 
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at Upcoming Industry and Investor Events in November
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
- Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies,... 
From Dyadic International, Inc.
Via AccessWire
Topics Regulatory Compliance Supply Chain
Exposures COVID-19 Legal Regulatory
Dyadic to Report Second Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,... 
From Dyadic International, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Dyadic to Present at Upcoming Events
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its... 
From Dyadic International, Inc.
Via AccessWire
Exposures COVID-19
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
- Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial - Goal of validating that C1 produced proteins are safe in humans and to... 
From Dyadic International, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Dyadic to Report First Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,... 
From Dyadic International, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.